Aduro BioTech Inc
-
Ticker
ADRO
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 51-200 Employees
- Based in Berkeley, California
Aduro BioTech, Inc., a clinical-stage immuno-oncology company, focuses on the development of technology platforms designed to stimulate robust and durable immune responses against cancer. Its lead product candidate is CRS-207, which is in a Phase IIb clinical trial for the treatment of metastatic pancreatic cancer and unresectable malignant pleural mesothelioma.
REPORT RATINGS
4.8 / 5.0 (124)
Aduro BioTech Inc reports have an aggregate usefulness score of 4.8 based on 124 reviews.
Aduro BioTech Inc
Most Recent Annual Report
MOST RECENT
2019 Annual Report and Form 10K
Older/Archived Annual Reports